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Abstract
Background—The conversion of prothrombin to thrombin is one of two non-duplicated
enzymatic reactions during coagulation. Thrombin has long been considered an optimal
anticoagulant target because it plays a crucial role in fibrin clot formation by catalyzing the
cleavage of fibrinogen, upstream coagulation cofactors, and platelet receptors. Although a number
of anti-thrombin therapeutics exist, it is challenging to use them clinically due to their propensity
to induce bleeding. Previously, we isolated a modified RNA aptamer (R9D-14) that binds
prothrombin with high affinity and is a potent anticoagulant in vitro.
Objectives—We sought to explore the structure of R9D-14 and elucidate its anticoagulant
mechanism(s). In addition to designing an optimized aptamer (RNAR9D-14T), we also explored
whether complementary antidote oligonucleotides can rapidly modulate the optimized aptamer’s
anticoagulant activity.
Methods and Results—RNAR9D-14T binds prothrombin and thrombin pro/exosite I with high
affinity and inhibits both thrombin generation and thrombin exosite I-mediated activity (i.e., fibrin
clot formation, feedback activity, and platelet activation). RNAR9D-14T significantly prolongs the
aPTT, PT, and TCT clotting assays, and is a more potent inhibitor than the thrombin exosite I
DNA aptamer ARC-183. Moreover, a complementary oligonucleotide antidote can rapidly (<2
min) and durably (>2 hrs) reverse RNAR9D-14T anticoagulation in vitro.
Conclusions—Powerful anticoagulation, in conjunction with antidote reversibility suggests that
RNAR9D-14T may be ideal for clinical anticoagulation in settings that require rapid and robust
anticoagulation, such as cardiopulmonary bypass, deep vein thrombosis, stroke, or percutaneous
coronary intervention.
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Coagulation involves a series of enzymatic reactions largely localized on vascular and
cellular surfaces that result in fibrin clot formation [1]. Thrombin, the final enzyme formed
during the common pathway of coagulation, establishes a positive feedback loop that
generates additional thrombin by activating factors V (FV) and VIII (FVIII), as well as by
cleaving platelet protease activated receptors (PARs) to activate platelets [2]. Moreover,
thrombin cleaves fibrinogen and generates fibrin monomers that form the clot meshwork [3].
Inappropriate or excessive thrombin generation can lead to thrombosis, which is currently
the leading cause of morbidity and mortality in the western world [4].
Thrombin’s structure possesses multiple regions that are involved in substrate interactions:
the catalytic active site and two extended surfaces, termed exosites, that participate in
macromolecular ligand binding [5]. Exosite I has been implicated in binding fibrinogen, FV,
FVIII, thrombomodulin (TM), and platelet PARs (for a review see [6]). Recent studies have
shown that exosite I exists on prothrombin in a precursor state termed proexosite I, which
presumably is involved in FVa/prothrombin interactions within the prothrombinase complex
[7–9]. In contrast, exosite II is not structurally mature on prothrombin and is only exposed
upon proteolysis and conversion to thrombin; exosite II has been implicated in binding FV,
FVIII, platelet GPIbα, and heparin (for a review see [6]).
Aptamers are single-stranded oligonucleotides that form three-dimensional structures that
allow them to bind to several types of molecules, including proteins. By binding to their
target protein with high affinity and specificity, aptamer anticoagulants can bury a large
surface area and directly inhibit protein-protein interactions that are essential for coagulation
[10, 11]. Aptamer anticoagulants have been generated against several clotting factors (e.g.,
factor VIIa, IXa, Xa, and thrombin) that demonstrate high affinity binding for their specific
target [11–15]. Importantly, aptamer activity can be modulated with either a matched
oligonucleotide antidote or universal antidote and thus represent controllable and potentially
safer anticoagulants [13, 16, 17].
A number of aptamers have been previously generated against thrombin, although none have
advanced clinically. ARC-183 (HD-1), a DNA aptamer isolated by Bock et al. that binds to
pro/thrombin pro/exosite I, demonstrated potential as an anticoagulant in animal
cardiopulmonary bypass (CPB) models [15, 18]. The aptamer was originally designed to
have a short half-life and rapid clearance in vivo, thus negating the need for antidote control.
However, rapid clearance of the therapeutic required continual administration, and as a
result ARC-183 clinical trials were terminated due to suboptimal dosing profiles in humans.
HD-22 (a DNA aptamer) and Tog-25t (a modified RNA aptamer) both bind to thrombin
exosite II and inhibit thrombin-mediated activation of platelets, but only have a nominal
effect on fibrinogen cleavage [19, 20]; thus, neither exosite II aptamer has advanced as a
clinical anticoagulant.
We sought to develop a high affinity, nuclease resistant and antidote-controllable
anticoagulant aptamer that would limit thrombin generation and inhibit thrombin activity.
Conversion of prothrombin to thrombin represents an attractive therapeutic target because it
is one of two non-redundant reactions within coagulation. By utilizing systematic evolution
of ligands by exponential enrichment (SELEX), we previously generated a modified RNA
aptamer (R9D-14) that binds to prothrombin and is a powerful anticoagulant [14]. In this
study, we examined the structure and function of this compound and characterized the
anticoagulant mechanism(s) of an optimized version of this aptamer (RNAR9D-14T).
Additionally, we generated an oligonucleotide antidote than can rapidly and stably reverse
aptamer-mediated anticoagulation in vitro.
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Human normal and prothrombin deficient citrated plasmas were purchased from George
King Biomedical, Inc. (Overland Park, Kansas). The citrated animal plasma was purchased
from Lampire Biological Laboratories, Inc. (Pipersville, PA). All of the purified coagulation
proteins (i.e., FV, FVIIa, FIXa, FXa, Protein C, Protein S, Protein Z, and prothrombin, as
well as α, β, and γ-thrombin) were purchased from Haematologic Technologies, Inc. (Essex
Junction, VT). Recombinant hirudin was purchased from Aniara (Manson, OH),
unfractionated sodium heparin was purchased from APP Pharmaceuticals, LLC
(Schaumburg, IL), and thrombin chromogenic substrate Pefachrome TH 8198 was
purchased from Centerchem, Inc. (Norwalk, CT). Bovine serum albumin (BSA) was
purchased from Calbiochem (Darmstadt, Germany), PEG-8000 was purchased from Fluka
Biochemika (Buchs, Switzerland), and phenol chloroform isoamyl (25:24:1) was purchased
from Invitrogen (Carlsbad, CA).
DNA/RNA Aptamers and DNA Antidote Oligonucleotides
The DNA aptamer ARC-183 and modified RNA aptamer Tog-25t were synthesized as
previously described [21]. The RNAR9D-14T aptamer sequence is 5'-GG(2'F-C)GG(2'F-U)
(2'F-C)GA(2'F-U)(2'F-C)A(2'F-C)A(2'F-C)AG(2'F-U)(2'F-U)(2'F-C)AAA(2'F-C)G(2'F-
U)AA(2'F-U)AAG(2'F-C)(2'F-C)AA(2'F-U)G(2'F-U)A(2'F-C)GAGG(2'F-C)AGA(2'F-
C)GA(2'F-C)(2'F-U)(2'F-C)G(2'F-C)(2'F-C)-3', and RNAmut is 5'-GG(2'F-C)GG(2'F-U)(2'F-
C)GA(2'F-U)(2'F-C)A(2'F-C)A(2'F-C)AG(2'F-U)(2'F-U)(2'F-C)AAA(2'F-C)G(2'F-
U)AA(2'F-U)AAG(2'F-C)(2'F-C)GG(2'F-C)G(2'F-U)A(2'F-C)GAGG(2'F-C)AGA(2'F-
C)GA(2'F-C)(2'F-U)(2'F-C)G(2'F-C)(2'F-C)-3', where (2’F-C) denotes a 2’Fluorocytosine
and (2’F-U) denotes a 2’Fluorouracil. The aptamers were transcribed in vitro and purified as
previously described [14]. Biotinylated ARC-183 (5’-Biotin-GGTTGGTGTGGTTGG) and
ARC-183mut (5’-Biotin-GGTGGTGGTTGTGGT) were purchased from Integrated DNA
Technologies, Inc. (Coralville, IA). The 5’- biotinylated RNAR9D-14T and RNAmut aptamers
were generated via in vitro transcription with the addition of a 4-fold molar excess of 5’-
Biotin-G-Monophosphate (TriLink Biotechnologies, San Diego, CA) [14]. Aptamer
preparations were renatured prior to use by dilution in Hepes-saline buffer (20 mM Hepes,
pH 7.4, 150 mM NaCl, and 2 mM CaCl2), unless otherwise indicated, and incubation at
65°C for 5 minutes, followed by cooling to ambient temperature.
The DNA antidotes (AO1: 5’-GAACTGTGTGATCGA-3’; AO2: 5’-
CGTTTGAACTGTGTG-3’; AO3: 5’-TATTACGTTTGAACT-3’; AO4: 5’-
TGGCTTATTACGTTT-3’; AO5: 5’-CCTCGTACATTGGCTTATTA-3’; AO6: 5’-
GTCTGCCTCGTACATTGGCT-3’; and scrAO 5’-TCTAAGCGATGGCTCAAGAC-3’)
were synthesized by Integrated DNA Technologies, Inc. (Coralville, IA).
Binding studies - nitrocellulose filter binding and surface plasmon resonance
Apparent binding affinity constants (Kd) were determined with a double-filter nitrocellulose
assay as previously described [14]. Aptamers were 32P 5’-end radiolabeled and incubated
with protein diluted in Hepes-saline buffer with 0.01% BSA at 37°C for 5 minutes. The
bound and unbound aptamer was separated by passing the mixture over a nitrocellulose filter
(Protran BA 85, Whatman Inc., Florham Park, NJ), and the fraction of bound aptamer was
quantified with a Storm 825 phosphoimager (GE Healthcare, Piscataway, NY). Nonspecific
aptamer binding was subtracted [22], and the data were fit with a non-linear regression
analysis for one site binding with the Prism software (GraphPad Software, Inc., La Jolla,
CA) to calculate the apparent Kd. For the thrombin competition bindings, the radiolabeled
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aptamer was pre-bound to human α-thrombin, various concentrations of unlabeled exosite I
or II ligands were added, and the assay was incubated for an additional 5 min at 37°C.
Surface plasmon resonance was performed with a BIAcore 3000 instrument, and data
analysis was performed with the BIAevaluation 4.1 software (BIAcore Inc, Piscattaway,
NJ). Biotinylated aptamers were refolded in Hepes-saline buffer, then immobilized on a
streptavidin chip (Biacore) at a flow rate of 5 µL/min at 25°C for 1–2 min to a final
immobilization level of 50–150 RU. Prothrombin (0.5–20 µg/mL) was diluted in degassed
Hepes-saline buffer and injected over the surface at a flow rate of 30 µL/min at 25°C for 5
minutes. The dissociation responses were monitored for 10 min, and the flow cells were
regenerated with a pulse of 0.05% SDS. Non-specific binding responses of prothrombin to
the mutant controls (RNAmut or ARC-183mut) were subtracted from the aptamer
sensorgrams. The specific binding curves were fitted globally to a 1:1 (Langmuir) binding
model to obtain the association and dissociation rate constants (ka and kd respectively), as
well as the binding affinity (KD).
Plasma clotting assays (aPTT, PT, TCT)
Activated partial thromboplastin time (aPTT), prothrombin time (PT), and thrombin clot
time (TCT) assays were performed on a model ST4 mechanical coagulometer (Diagnostica
Stago, Parsnippany, NJ) in Hepes-saline buffer as previously described [21]. For the aPTT,
citrated normal human or animal platelet poor plasma (PPP) (50 µL) was incubated with
TriniClot aPTT S (Trinity BioTech, Bray, Co Wicklow, Ireland) (50 µL) at 37°C for 5 min.
Aptamer (5 µL) was added, the mixture was incubated at 37°C for another 5 min, and CaCl2
(50 µL) was added to initiate the assay. The aPTT DNA antidote reversal assays were run as
described, except that antidote (5 µL) was added to the activated, anticoagulated plasma and
incubated for various time points (2 min - 2 hrs) at 37°C, which was followed by the
addition of CaCl2 and assay initiation [13]. For the PT, human PPP (50 µL) was incubated
with aptamer (5 µL) at 37°C for 5 min. TriniClot PT Excel reagent (Trinity BioTech, Bray,
Co Wicklow, Ireland) (100 µL) was added to initiate the reaction. For the TCT assay,
aptamer (5 µL) was added to purified human α-thrombin (10 nM final, 100 µL) and
incubated at 37°C for 200 sec. Normal human PPP or prothrombin deficient PPP (50 µL)
was added to the prebound thrombin/aptamer solution (105 µL) to initiate the reaction.
Thrombin small peptide substrate and antithrombin kinetics
The small peptide assays were performed at room temperature in 96-well flat bottom
microtiter plates (Corning Incorporated, Corning, NY) in Hepes-saline buffer. Aptamer (300
nM) was incubated with human α-thrombin (10 nM) for 5 min at 37°C, and thrombin
chromogenic substrate Pefachrome TH 8198 (0–0.5 mM) was added to a total volume of
100 µL. Substrate cleavage was measured at an absorbance of 405 nm with a Power Wave
XS2 kinetic microplate spectrophotometer (BioTek, Winooski, VT). The Km and Kcat were
determined by a nonlinear regression analysis with the Prism software according to
Michaelis-Menton kinetics (GraphPad Software, Inc., La Jolla, CA).
The antithrombin kinetic (AT) assays were performed as previously described [23] in
Hepes-saline buffer with 0.01% BSA and 1 mg/mL PEG 8000. Briefly, aptamer was
incubated with thrombin (3 nM final) at ambient temperature for 5 min. Antithrombin (500
nM final) was added (450 µL total), and samples (50 µL) were withdrawn at various time
points (0–60 min). Pefachrome TH 8198 (50 µL) was added, and substrate cleavage was
measured at 405 nm on a kinetic microplate spectrophotometer at room temperature
(BioTek, Winooski, VT). The second order rate constant of inhibition (k2) was calculated as
previously described [24].
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For SDS-PAGE and silver stain analysis, aptamer (5 µM) was incubated with human α-
thrombin (0.5 nM) for 5 min at 37°C in Hepes-saline buffer. Human factor V (300 nM) was
added (40 µL total), and samples (5 µL) were removed at various time points (0–30 min) and
subjected to SDS-PAGE under reducing conditions on a pre-poured 4–15% polyacrylamide
gradient gel (Biorad, Hercules, CA). The gels were silver stained with a Bio-Rad Silver
Stain kit (Biorad) according to the manufacturer’s instructions.
To assess FVa activity, various concentrations of aptamer (0–500 nM, 5 µL) were diluted in
Hepes-saline buffer with 0.01% BSA and incubated with human α-thrombin (3 nM, 5 µL)
for 5 min at 37°C. Human factor V (250 ρM, 5 µL) was added, and samples (8 µL) were
removed at various time points (0–7 min) and immediately diluted into a prothrombinase
mixture of 5 nM human FXa, 40 µM PC/PS/PE lipid vesicles, and 500 µM Pefachrome TH
8198 (42 µL). Large, phosphatidylcholine (PC), phosphatidylserine (PS), and
phosphatidylethanolamine (PE) (Avanti Polar Lipids, Alabaster, Alabama) unilamellar
vesicles were prepared as previously described [25]. Human prothrombin (500 nM, 50 µL)
was added to initiate the reaction, and substrate cleavage was measured at 405 nm on a
kinetic microplate spectrophotometer at 37°C (BioTek, Winooski, VT). The data were fit
during the linear portion of the reaction to obtain the rate of chromogenic substrate cleavage
(ΔA405/time). A control assay was performed in parallel where FV was fully activated with
thrombin in the absence of RNA and diluted into prothrombinase containing aptamer to
quantify aptamer inhibition of prothrombin cleavage. The experimental rates were
normalized to the respective control rates to correct for aptamer inhibition of prothrombin
cleavage, and the data are presented as a percentage of FVa cofactor activity of fully
activated FV. The lines were arbitrarily drawn with the Prism software (GraphPad Software,
Inc., La Jolla, CA).
Thrombin-mediated platelet activation
Platelets were purified from freshly drawn blood from healthy volunteers under a Duke
University Institutional Review Board approved protocol. Aptamer inhibition of thrombin-
mediated platelet activation was assessed as previously described [21, 26]. Briefly, aptamer
(0.39 – 400 nM final, 5 µL) was diluted in Hepes-saline buffer with 0.01% BSA and
incubated with α-thrombin (1 nM final, 20 µL) at 37°C for 5 min. Purified platelets (25 µL)
were added, and the reaction was incubated at 37°C for 15 min. The platelets were stained
with 75 ng of a fluorescent anti-CD62P (P-selectin) or isotype control antibody
(eBioscience, San Diego, CA) (50 µL) at room temperature for 30 minutes, then washed and
analyzed with a FACScalibur flow cytometer (Becton Dickinson, Franklin Lakes, NJ). The
data were analyzed with the Cell Quest analysis software, version 3.3 (Becton Dickinson).
Thrombin generation
Thrombin generation in a purified system was measured as previously described [11]. For
complete prothrombinase experiments, aptamer (0.3–5 µM, 5 µL) diluted in reaction buffer
(Hepes-saline buffer with 0.01% BSA and 1 mg/mL PEG 8000) was incubated with 1.4 µM
prothrombin (5 µL) at 37°C for 5 min. FXa (0.2 nM), FVa (30 nM), and PC/PS/PE lipids (40
µM) (10 µL total) were incubated at 37°C for 5 min to allow for complex assembly, and
prebound prothrombin/aptamer was added to initiate the reaction. Aliquots (1 µL) were
withdrawn at various time points (0–10 min), diluted in quench buffer (20 mM Hepes pH
7.4, 150 mM NaCl, 50 mM EDTA, and 1 mg/mL PEG 8000; 49 µL), and thrombin
chromogenic substrate Pefachrome TH 8198 (50 µL) was added at a final concentration of
100 µM. Substrate cleavage was measured at 405 nm on a kinetic microplate
spectrophotometer at ambient temperature (BioTek, Winooski, VT). The initial rates of
thrombin substrate cleavage were converted to thrombin concentration based upon the
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specific activity of thrombin Pefachrome TH8198 cleavage, as was determined in a separate
assay with known concentrations of purified commercial α-thrombin. The data were fit
during the linear portion of the reaction to obtain the thrombin generation rate (µM/min).
The experimental rates were normalized to the rate for a mock reaction (no aptamer). Partial
prothrombinase experiments contained 100 nM FXa and 40 µM PC/PS/PE lipids (no FVa),
or 2 nM FXa and 30 nM FVa (no lipids).
Serum stability
The aptamer was 32P 5’-end radiolabeled as previously described (5,000 cpm/µL, 15 µL)
[14] and incubated with human serum (35 µL) at 37°C. Time points (0–24 hr, 3 µL) were
diluted in Tris-EDTA buffer (10 mM Tris, pH 7.5 and 0.1 mM EDTA; 40 µL), extracted
with phenol chloroform isoamyl (50 µL), heated at 65°C for 5 minutes, run on a 12%
denaturing acrylamide gel, and quantified by phosphoimager analysis (Storm 825
phosphoimager, GE Healthcare, Piscataway, NY).
Antidote gel mobility shift
32P 5’-end radiolabeled aptamer (5,000 cpm/µL; 6 µL) was mixed with unlabeled aptamer
(125 nM), diluted in Hepes-saline buffer with 0.01% BSA, and incubated with various
concentrations of DNA antidote (62.5–500 nM) at 37°C for 5 minutes. Aptamer/antidote
control duplex formation was ensured by heating the aptamer/antidote mixture to 95°C and
slow cooling to ambient temperature. Sample aliquots (6 µL) were subjected to native-
PAGE on an 8% polyacrylamide gel at 4°C and quantified by phosphoimager analysis.
Statistical analysis
The data were statistically analyzed with a two-tailed, paired t-test with the Prism software
(GraphPad Software, Inc., La Jolla, CA). P-values less than 0.05 were considered
statistically significant.
Thrombin peptide alignment and sequence analysis
Thrombin beta-chain peptide sequences were downloaded from the NCBI protein
HomoloGene database (http://www.ncbi.nlm.nih.gov) and aligned with the MacVector 7.2
software (MacVector, Inc., Cary NC). The percent sequence similarity (percent homology)
to the human sequence was calculated with the Clustal W2 software (http://www.ebi.ac.uk/
Tools/msa/clustalw2/).
Results
Delineating the essential RNA sequence within aptamer R9D-14
The full-length prothrombin aptamer R9D-14 is an 80 nucleotide long, 2’Fluoro-pyrimidine
modified RNA aptamer that we originally generated by systematic evolution of ligands with
exponential enrichment (SELEX) against the gamma carboxylic glutamic acid (GLA)
proteome of human plasma [14]. To determine the minimal RNA sequence required for high
affinity aptamer binding and functionality, R9D-14 was truncated by systematic deletion of
the 5’ and 3’ termini. The shortest RNA derivative that retains high affinity binding and
anticoagulant activity is 58 nucleotides and was renamed RNAR9D-14T. A point mutant
control aptamer (RNAmut) was created by mutating three nucleotides (Figure 1).
Aptamer-protein binding affinity and specificity
The majority of anticoagulant aptamers bind both the zymogen and enzyme [11–13, 27].
Nitrocellulose filter binding indicates that RNAR9D-14T binds with high affinity to both
human prothrombin (apparent Kd=10 nM) and α-thrombin (apparent Kd=1 nM), while
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RNAmut shows weak binding toward either protein (Figure 2a). Additional nitrocellulose
filter binding studies with structurally related human coagulation proteins (e.g., FVIIa, FIXa,
FXa and Protein C, S, and Z) indicate that RNAR9D-14T shows very weak binding toward
these coagulation factors (apparent Kd>1,000 nM) and thus specifically recognizes a surface
that is unique to prothrombin/thrombin (Figure 2b). Surface plasmon resonance (SPR) was
also performed to obtain more information regarding the kinetics of RNAR9D-14T
prothrombin binding, and the data were compared to the pro/thrombin binding DNA
aptamer ARC-183. Compared to ARC-183, RNAR9D-14T has a greater than 40-fold higher
affinity for prothrombin (KD RNAR9D-14T=1.4 nM and ARC-183=60.7 nM), which is a
result of both a faster association rate (Ka=8.97×105 vs. 5.03×104 1/Ms, respectively) and a
slower dissociation rate (Kd=1.26×10−3 vs. 3.05×10−3 1/s, respectively) compared to
ARC-183 (Supplemental Figure 1).
Binding competition experiments with several thrombin exosite ligands were performed to
localize the RNAR9D-14T binding site. Hirudin, thrombomodulin (TM), and ARC-183 all
compete with RNAR9D-14T for human α-thrombin binding, while heparin and the RNA
aptamer Tog-25t do not (Figure 3a,b). Additionally, RNAR9D-14T has a decreased affinity
for β-thrombin (apparent Kd=20 nM) and very weak affinity for γ-thrombin (apparent
Kd>1,000 nM), which have altered exosite I surfaces and decreased activity toward
fibrinogen (data not shown) [28, 29]. Collectively these data indicate that RNAR9D-14T binds
specifically to (pro)thrombin (pro)exosite I.
Nuclease resistance and serum stability
The data so far indicate that RNAR9D-14T and ARC-183 both bind to (pro)thrombin
(pro)exosite I, although RNAR9D-14T has a higher binding affinity. Additionally, the two
aptamers differ in their chemical composition - ARC-183 is comprised of unmodified DNA,
while RNAR9D-14T is comprised of 2’Fluoro-pyrimidine modified RNA [14, 15]. To
compare the stability of these oligonucleotides, the aptamers were radiolabeled and
incubated with human serum over a period of 24 hours. Unlike the DNA aptamer ARC-183,
which has a half-life of less than 2 hr and was completely degraded within 4 hr,
RNAR9D-14T has an extended half-life of greater than 6 hr (Figure 4). Thus, RNAR9D-14T is
much more resistant to human serum nucleases than ARC-183.
Clinical anticoagulation assays
The ability of RNAR9D-14T to anticoagulate human plasma was tested with several clinical
clotting assays. RNAR9D-14T dose-dependently prolonged the activated partial
thromboplastin (aPTT) and prothrombin time (PT) and was more robust than ARC-183,
while RNAmut had no effect (Figure 5a). At 4 µM, RNAR9D-14T increased the aPTT clotting
time from 31 sec to 664 sec (21-fold), and increased the PT clotting time to from 13 sec to
greater than 15 min (exceeded the standard assay limit). In contrast, 4 µM of ARC-183 only
increased the aPTT time to 86 sec (2.7-fold) and the PT time to 62 sec (4.8-fold) (Figure 5a).
Thus, the clinical clotting data indicate that RNAR9D-14T anticoagulation is specific and
much more potent than ARC-183.
Fibrinogen binding to thrombin exosite I is essential for fibrin generation, which forms the
meshwork of a blood clot. Because RNAR9D-14T binds exosite I, we tested its impact on
fibrinogen cleavage in both normal and prothrombin deficient (<3% activity) plasma with a
thrombin clot time assay (TCT). While RNAmut had no effect, 1 µM RNAR9D-14T increased
the clot time from approximately 53 sec to greater than 15 minutes (exceeded the standard
assay limit) (Figure 5b). Thus, RNAR9D-14T binding to thrombin exosite I impairs fibrin clot
formation.
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Thrombin active site function
Several exosite I ligands have been reported to have allosteric effects on thrombin active site
activity [30–34]. We therefore studied the impact of RNAR9D-14T binding to exosite I on the
thrombin active site by monitoring small peptide chromogenic substrate cleavage. At super-
saturating concentrations, RNAR9D-14T binding, compared to RNAmut binding, only slightly
decreased the Km (9 vs. 24 µM, respectively; p=0.06) and slightly decreased the kcat (72.7
vs. 107.9 sec−1, respectively; p=0.04) (Table 1). Further studies regarding the aptamer’s
impact on the thrombin active site were performed with a physiological, active site-binding
macromolecule – the serine protease inhibitor antithrombin (AT). Previous aptamer studies
have shown that Tog-25t exosite II binding decreased the second order rate constant (k2) of
AT inhibition by approximately 3-fold [23], while ARC-183 exosite I binding had little
effect [35]. Similar to ARC-183, a super-saturating concentration of RNAR9D-14T had a non-
significant effect on AT inhibition and increased the k2 constant 1.3-fold compared to
RNAmut (3.43×105 vs. 2.56×105 M−1 min−1, respectively; p=0.09) (Table 1). Collectively,
the kinetic data suggest that RNAR9D-14T has only a subtle impact on thrombin active site
structure and activity. Thus, we hypothesized that RNAR9D-14T anticoagulation is primarily
due to inhibition of exosite I mediated protein-protein interactions.
Thrombin activation of FV
Previous studies have shown that exosite I ligands inhibit FV and FVIII cleavage and
decrease thrombin feedback activity [27, 36]. To test the impact of RNAR9D-14T on cofactor
activation, thrombin-mediated cleavage of purified FV was analyzed via silver stain analysis
and FVa cofactor activity in a purified prothrombinase system. Compared to RNAmut,
RNAR9D-14T delayed FV cleavage for greater than 10 minutes and inhibited Arg709
cleavage for greater than 30 minutes, thereby preventing the appearance of the FVa heavy
chain (VaH) (Figure 6a). RNAR9D-14T also dose-dependently impaired FVa cofactor activity
compared to a similar concentration of RNAmut (Figure 6b). Interestingly, a previous study
by Thorelli et al. reported that a FV mutant that cannot be cleaved at Arg709 has similarly
decreased FVa activity [37]. Thus, RNAR9D-14T binding to thrombin exosite I inhibits
cleavage of Arg709 and decreases FVa cofactor activity.
Thrombin-mediated platelet activation
The initial small amounts of thrombin formed activate platelets and prime the system for a
rapid burst of thrombin generation [1]. Thrombin exosite I binds and mediates active site
cleavage of platelet protease activated receptors (PARs), which results in platelet
degranulation and upregulation of the P-selectin (CD62P) surface receptor [38, 39].
RNAR9D-14T prevented thrombin-mediated platelet activation in a dose-dependent manner,
and at saturating concentrations prevented greater than 90% of platelet activation; in
contrast, RNAmut had no effect (Figure 7). Therefore, RNAR9D-14T exosite I binding also
potently inhibits thrombin exosite I-mediated platelet activation.
Thrombin generation
Because RNAR9D-14T binds to both human prothrombin and thrombin, the aptamer may
function as an anticoagulant by inhibiting both thrombin generation and thrombin activity.
The impact of the aptamer on prothrombin cleavage was assessed by monitoring thrombin
generation in a purified system with the prothrombinase complex (purified FXa and FVa)
pre-assembled on lipid vesicles. At physiological concentrations of prothrombin,
RNAR9D-14T caused a dose dependent decrease in the rate of thrombin generation and
decreased the rate of thrombin generation by greater than 70% at high concentrations (5
µM); similar concentrations of RNAmut had no effect (Figure 8a,b). Thus, RNAR9D-14T
inhibits both thrombin generation and thrombin exosite I function.
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The current literature suggests that FVa binds to prothrombin within the prothrombinase
complex via proexosite I [7–9], and several proexosite I-binding ligands prevent
prothrombin cleavage in a FVa-dependent manner [27, 40]. To determine if RNAR9D-14T
has a similar mechanism of anticoagulation, thrombin generation assays were repeated with
various combinations of the prothrombinase components. A partial prothrombinase complex
of FXa with FVa (no lipids) was sensitive to RNAR9D-14T inhibition, while FXa with lipids
(no FVa) was not sensitive (data not shown). Therefore, similar to other proexosite I ligands,
RNAR9D-14T blocks thrombin generation in a FVa-dependent manner.
Antidote reversibility
Anticoagulant RNA aptamers can be formulated to circulate in vivo for 24–30 hours [41].
Therefore, in the event of clinical complications, such as hemorrhage, physicians need to
rapidly and safely reverse anticoagulation. We have previously described the design of
complementary oligonucleotide antidotes to modulate anticoagulant aptamers [13, 16].
Because RNAR9D-14T is an extremely potent and stable anticoagulant, we sought to design
antidotes that can rapidly control its anticoagulant activity and improve its safety profile.
Six complementary DNA antidote sequences were designed to bind to various regions
across RNAR9D-14T via Watson-Crick base pairing and tested for their ability to disrupt
aptamer binding [16]. Antidotes 5 and 6 completely reversed RNAR9D-14T binding to human
prothrombin in a nitrocellulose filter binding assay, while antidotes 1–4 only partially
reversed binding (data not shown). Native gel electrophoresis showed that a four-fold molar
excess of AO6 formed a duplex with more than 80% of free RNAR9D-14T aptamer, while a
four-fold molar excess of a scrambled antidote control (scrAO) did not form a duplex
(Figure 9a). Additionally, a four-fold molar excess of AO6 was able to reverse 96% of
RNAR9D-14T anticoagulation in an aPTT within two minutes, and 78% of RNAR9D-14T
anticoagulation after two hours; in contrast, a scrambled antidote did not reverse
RNAR9D-14T anticoagulation (Figure 9b). Thus, for clinical applications, RNAR9D-14T can
be formulated to have an extended half-life, yet can be rapidly controlled with an antidote.
Animal cross-reactivity and anticoagulation
Because aptamers can bind to their therapeutic targets with extremely high specificity,
aptamers have been isolated that do not cross-react with orthologous proteins from other
animals [20]. RNAR9D-14T was tested for its ability to anticoagulate plasma from several
species in an aPTT assay. At 2 µM, RNAR9D-14T robustly anticoagulated human (19-fold
increase in clotting time), rhesus (7.6-fold increase), and pig plasma (4.2-fold increase), but
showed decreased activity in dog, rabbit, sheep, mouse, rat, and cow plasma (Supplemental
Figure 2a). The apparent binding affinity of RNAR9D-14T toward purified thrombin or
prothrombin from several of these species was also assessed to confirm the species cross-
reactivity results. RNAR9D-14T binds to porcine thrombin (apparent Kd=5 nM) with a similar
binding affinity as human thrombin (apparent Kd=1 nM), but shows little binding affinity
toward cow thrombin, rat thrombin, or mouse prothrombin (apparent Kd s>1,000 nM;
Supplemental Figure 2b). Thus, the aptamer-binding epitope on exosite I appears to be
conserved in humans, primates, and pigs, but not cows or rodents. Moreover, RNAR9D-14T
anticoagulation appears to be specific for pro/thrombin binding because bovine plasma was
not anticoagulated by a high dose of RNAR9D-14T, which has a very weak affinity toward
bovine thrombin.
Discussion
Because thrombin is the final enzyme formed during the coagulation cascade and plays a
number of key roles in fibrin clot formation, thrombin has been an important target for
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anticoagulant therapy. Although several direct thrombin inhibitors are clinically available
(e.g., lepirudin, argatroban, and bivalrudin), they can be challenging to use because they are
associated with an increased risk of bleeding and cannot be easily reversed with an antidote
[42]. Additionally, several aptamers have been developed against thrombin (e.g., ARC-183,
HD-22, and Tog-25t), although none have advanced clinically due to chemical instability,
rapid clearance in vivo, and/or limited anticoagulant activity [15, 19, 20]. Here we describe
the structure and function of a 2’F-modified nuclease resistant RNA aptamer (RNAR9D-14T)
that binds to prothrombin/thrombin and is a potent anticoagulant. RNAR9D-14T binds
prothrombin at proexosite I and prevents thrombin generation in a FVa-dependent manner.
Additionally, although RNAR9D-14T binding to thrombin has only a minor impact on active
site function, it severely impairs coagulation by inhibiting exosite I mediated function (i.e.,
fibrin clot formation, FV activation, and platelet activation).
Binding studies indicate that RNAR9D-14T and ARC-183 bind to the same region on
thrombin (exosite I). An analysis of RNAR9D-14T animal cross-reactivity highlights key
residues within exosite I that may be important for aptamer binding. An alignment of the
human, rhesus, porcine, bovine, rat, and mouse thrombin beta chain amino acid sequence
shows that two exosite I amino acids (Ile24 and Ile79) are conserved in only the species that
RNAR9D-14T robustly anticoagulates (i.e., human, rhesus, and pig) (Supplemental Figures 2a
and 3). Interestingly, ARC-183 binding forms direct contacts with these surface residues in
thrombin exosite I [43], and the species cross reactivity data suggest that these residues may
be important for RNAR9D-14T binding as well.
Although RNAR9D-14T and ARC-183 have a similar mechanism of anticoagulation (i.e., pro/
exosite I inhibition), RNAR9D-14T has a different chemical composition that results in a
higher binding affinity and increased plasma stability (Figure 4, and Supplemental Figure 1).
Moreover, RNAR9D-14T (58 nucleotides) is much larger than ARC-183 (15 nucleotides) and
may therefore cover a larger area on the protein surface. Consequentially, RNAR9D-14T
appears to be a more powerful anticoagulant in plasma clotting assays (Figure 5a). Although
RNAR9D-14T binds prothrombin/thrombin with high affinity, a high concentration is
required to saturate prothrombin, which has an estimated concentration of 1.4 µM in human
blood. Additionally, only approximately 30–40% of the aptamer folds into the high affinity
conformation that can bind to prothrombin and thrombin (Figure 2a and data not shown); the
combination of inefficient aptamer folding and a high target concentration mean that the
saturating dose of RNAR9D-14T is greater than 5 µM. Future experiments should be
performed to see if aptamer folding can be improved, thereby reducing the dose required for
robust anticoagulation, or to determine if combining RNAR9D-14T with another
anticoagulant aptamer (i.e., FIXa and Xa aptamers) can reduce the dose required.
Because RNAR9D-14T is such a robust anticoagulant, we designed several complementary
DNA oligonucleotide antidotes to bind to the aptamer and alter its three-dimensional
conformation, thus resulting in an inactive stable complex. RNAR9D-14T was rapidly and
durably reversed with a complementary antidote in vitro, which makes this compound an
attractive candidate for further development as a robust, yet rapidly controllable
anticoagulant. Future in vivo studies of anticoagulation with RNAR9D-14T alone, or in
combination with other RNA aptamers and their antidotes are needed to assess the
applicability of aptamer/antidote anticoagulation in clinical settings where safe yet effective
anticoagulation is essential, such as cardiopulmonary bypass, deep vein thrombosis, stroke,
or percutaneous coronary artery intervention.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. The M-fold predicted secondary structure of RNAR9D-14T and RNAmut
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Figure 2. RNAR9D-14T binds both human prothrombin and thrombin with high affinity and
specificity
A) Nitrocellulose filter binding of the aptamer and mutant with human prothrombin and
thrombin. Circles (●) represent RNAR9D-14T with α-thrombin, squares (■) are RNAR9D-14T
with prothrombin, diamonds (◆) are RNAmut with α-thrombin, and triangles (▲) are
RNAmut with prothrombin. The data represent the average ± the SEM of triplicates. B)
Nitrocellulose filter binding of RNAR9D-14T to human coagulation factors. Squares (■)
represent FVIIa, triangles (▲) are FIXa, inverted triangles (▼) are FXa, diamonds (◆) are
Protein C, circles (●) are Protein S, and open squares (□) are Protein Z. The data represent
the average ± the SEM of duplicates.
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Figure 3. RNAR9D-14T competes with exosite I, but not exosite II ligands for human α-thrombin
binding
A) Binding competition between RNAR9D-14T and various thrombin exosite I ligands.
Squares (■) represent the ARC-183 DNA aptamer (0–200 nM), triangles (▲) represent
recombinant hirudin (0–100 nM), and circles (●) represent rabbit thrombomodulin (0–100
nM). The data represent the mean ± SEM of triplicates. B) Binding competition between
RNAR9D-14T and various exosite II ligands. Squares (■) represent the Tog-25t RNA
aptamer (0–100 nM), while circles (●) represent heparin (0–20 U/mL). The data represent
the mean ± SEM of triplicates.
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Figure 4. The modified RNA aptamer RNAR9D-14T is more stable in human serum compared to
the DNA aptamer ARC-183
Denaturing gel analysis of A) ARC-183 and B) RNAR9D-14T stability in human serum. The
aptamers were 32P 5’-end radiolabeled (5,000 cpm/µL), incubated with human serum, and
samples were withdrawn at the indicated times and run on a 12% denaturing acrylamide gel;
min (’) and hours (h).
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Figure 5. RNAR9D-14T prolongs the aPTT, PT, and TCT clotting time and is a more potent
anticoagulant than ARC-183
A) Effect of RNAR9D-14T, RNAmut, and ARC-183 on the aPTT and PT in normal human
plasma. Squares (■) represent ARC-183 in the aPTT, triangles (▲) are RNAR9D-14T in the
aPTT, inverted triangles (▼) are ARC-183 in the PT, circles (●) are RNAR9D-14T in the PT,
pluses (+) are RNAmut in the aPTT, and X’s (×) are RNAmut in the PT. The data were
normalized to the baseline clot time and represent the mean ± SEM of triplicates. B) Effect
of RNAR9D-14T and RNAmut on the thrombin clot time (TCT). Squares (■) represent
RNAR9D-14T in normal plasma, triangles (▲) are RNAmut in normal plasma, circles (●) are
RNAR9D-14T in prothrombin deficient plasma (<3% activity), and diamonds (◆) are
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RNAmut in prothrombin deficient plasma. The data were normalized to the baseline clot time
and represent the mean ± the SEM of triplicates.
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Figure 6. RNAR9D-14T inhibits factor V activation by thrombin
A) Silver stain analysis of FV activation by thrombin in the presence of saturating
RNAR9D-14T or RNAmut. FV denotes uncleaved factor V, VaH is the factor Va heavy chain,
and VaL is the factor Va light chain. The numbers above the lanes indicate the assay
incubation time in minutes (’), and the numbers on the left represent the protein standard
sizes. B) Chromogenic assay for FVa cofactor activity. FV (250 ρM) was activated by
thrombin (3 nM) in the presence of RNAR9D-14T or RNAmut and time points were diluted
into a prothrombinase chromogenic assay where the rate of thrombin generation was
dependent upon the concentration of FVa formed. Squares (■) represent no aptamer,
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triangles (▲) are 500 nM RNAR9D-14T, inverted triangles (▼) are 100 nM RNAR9D-14T,
diamonds (◆) are 20 nM RNAR9D-14T, and circles (●) are 500 nM RNAmut. The data were
normalized to a parallel control experiment where FV was fully activated in the absence of
RNA and are expressed as a percentage of the FVa activity of fully activated FV. The data
are single experiments that are representative of three independent experiments.
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Figure 7. RNAR9D-14T inhibits thrombin-mediated platelet activation
Thrombin was incubated with purified human platelets in the presence of aptamer, and
platelet degranulation was measured via flow cytometry with an anti-CD62P (P-selectin)
antibody. Unstim represents resting platelets (no thrombin added), the black bars represent
RNAR9D-14T preincubated with 1 nM of human thrombin, and the gray bars represent
RNAmut preincubated with 1 nM human thrombin. The data represent the mean ± SEM of
duplicates and are representative of data with three different platelet donors.
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Figure 8. RNAR9D-14T inhibits thrombin generation in a purified prothrombinase system
A) Thrombin formation curves, as measured via a discontinuous purified prothrombinase
assay with a physiological concentration of prothrombin (1.4 µM). Circles (●) represent no
addition of aptamer, squares (■) are 5 µM RNAR9D-14T, and triangles (▲) are 5 µM
RNAmut. The data represent the mean ± SEM of two independent preparations of
prothrombinase. B) Dose dependent response of the rate of prothrombin activation with
increasing concentrations of RNAR9D-14T. The data were normalized to the rate in the
absence of aptamer and represent the mean ± SEM for three independent experiments.
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Figure 9. DNA antidote oligonucleotide 6 forms a duplex with RNAR9D-14T and reverses
anticoagulation in vitro
A) Native gel analysis of antidote oligonucleotide 6 (AO6) binding to radiolabeled
RNAR9D-14T. Radiolabeled aptamer and unlabeled aptamer (125 nM) were mixed and
incubated with various concentrations of DNA antidote (62.5–500 nM) at 37°C for 5
minutes. Untreated radiolabeled RNAR9D-14T (U), and RNAR9D-14T denatured and
complexed with AO6 before gel loading (C). Lanes 1–4 show a decrease in the
AO6:RNAR9D-14T molar ratio from 4:1 to 0.5:1 in two-fold increments. A scrambled
antidote (scrAO) was incubated with RNAR9D-14T at a 4:1 ratio at 37°C (S) or heated to
95°C and slow cooled (SC) prior to loading. B) aPTT time course for AO6 reversal of
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RNAR9D-14T anticoagulation. Normal human plasma was anticoagulated with RNAR9D-14T,
antidote was added and incubated for various time points at 37°C, and the aPTT clotting
time was measured. Mock is a standard aPTT assay with no aptamer (baseline); aptamer
alone is a standard aPTT assay with 1 µM of RNAR9D-14T and no antidote. The gray bars
represent addition of 4 µM AO6, while white bars represent addition of 4 µM scrAO. The
data were normalized to the baseline clotting time and represent the mean ± SEM of
duplicates.
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Table 1
Thrombin small peptide and Antithrombin kinetics with RNAR9D-14T and RNAmut.
Small peptide kinetics AT kinetics
Km (mM) kcat (sec_1) k2 (M1 min1)
No aptamer 0.020 ± 0.002 100.5 ±6.7 2.18 ± 0.29×105
RNAR9D-14T 0.009 ±0.001 72.7 ±6.1 3.43 ± 0.35×105
RNAraut 0.024 ± 0.004 107.9 ±8.6 2.56 ± 0.34×105
AT=Antithrombin; the data represent the mean ± the SEM of three independent experiments performed in triplicate.
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